Cyclic Plasmenylethanolamines Bypass Metabolic Defects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for rhizomelic chondrodysplasia punctata (RCDP) and other plasmalogen deficiency disorders are ineffective due to the inability to effectively metabolize dietary plasmalogen precursors into plasmalogen species, leading to severely reduced plasmalogen levels and impaired cellular function.
Innovation Solution
Administration of cyclic plasmenylethanolamines, which are converted into plasmalogen species within the body, thereby elevating plasmalogen levels and bypassing the inefficient metabolic pathways of peroxisomal biogenesis disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If dietary plasmalogen precursors are administered to treat plasmalogen deficiency disorders, then plasmalogen levels should increase, but the precursors cannot be effectively metabolized into plasmalogen species due to peroxisomal biogenesis disorders
Solution Approach 1:
The patent uses alkyl glycerols as intermediary substances that can be metabolized by peroxisomes to produce plasmalogen species. These intermediaries bypass the defective metabolic pathways and directly generate the needed plasmalogens through alternative routes involving enzymes like GNPAT and AGPS.
Solution Approach 2:
The invention changes the chemical parameters of the administered substance by using modified plasmalogen precursors with specific alkyl chains and glycerol backbones that are recognized and processed by residual peroxisomal enzymes, thereby enabling metabolic conversion despite the underlying genetic defects.
2Quantity of substance
If high doses of plasmalogen precursors are administered to overcome metabolic deficiency, then plasmalogen levels may increase, but the treatment requires very high doses and lengthy time-courses
Solution Approach 1:
The patent employs precursors that are pre-configured with the necessary alkyl and glycerol structures close to the final plasmalogen product. This preliminary structuring allows the body's enzymes to complete only the final steps of plasmalogen synthesis, dramatically reducing the time and dose required compared to administering basic fatty alcohol precursors.
3Reliability
If plasmalogen levels are severely reduced in peroxisomal biogenesis disorders, then cellular function becomes impaired, but no effective disease-modifying therapy is available
Solution Approach 1:
The invention enables the patient's own peroxisomal enzymes (GNPAT, AGPS, and other pathway enzymes) to perform the therapeutic work by providing them with suitable substrates (alkyl glycerols). The body's existing metabolic machinery is harnessed to produce the needed plasmalogens, eliminating the need for external plasmalogen replacement and allowing sustained endogenous production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic plasmenylethanolamines effectively augment plasmalogen levels in tissues and plasma, improving cellular function and potentially treating or preventing disorders like RCDP, Alzheimer's disease, and Parkinson's disease by normalizing plasmalogen deficiencies.
Implementation Method 1
cyclic plasmenylethanolamines, which are converted into plasmalogen species within the body
Data Source
AI summary
Provided herein are cyclic plasmenylethanolamines and plasmalogen precursors of formula A, wherein R1 and R2 are each, independently, a saturated, unsaturated, or polyunsaturated hydrocarbon group. Methods and uses thereof in the treatment of plasmalogen deficiency are also described. Cyclic plasmenylethanolamines described herein may act as plasmalogen precursors which, following administration, may be converted to at least one plasmalogen species, thereby elevating the plasmalogen level in a subject.